{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:56:36Z","timestamp":1789390596143,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116161","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:15:41Z","timestamp":1764868541000},"page":"116161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study"],"prefix":"10.1016","volume":"233","author":[{"given":"Manuel Ruiz","family":"Borrego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P\u00e1ez","family":"L\u00f3pez-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia Margel\u00ed","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-4726","authenticated-orcid":false,"given":"Mar\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador Blanch","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6880-0301","authenticated-orcid":false,"given":"Jos\u00e9 \u00c1ngel","family":"Garc\u00eda-Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Ant\u00f3n","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Alba","family":"Conejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Blancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kepa","family":"Amillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Santasusagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-0345","authenticated-orcid":false,"given":"Marc Antoine","family":"Benderra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-1346","authenticated-orcid":false,"given":"Daniel","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-3665","authenticated-orcid":false,"given":"Gabriele","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116161_bib1","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P3-09-22","article-title":"Abstract P3-09-22: phenomenal: Efficacy and safety of liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases","volume":"31","author":"Borrego","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116161_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000024","article-title":"Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers","volume":"1","author":"Berghoff","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116161_bib3","first-page":"894","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib4","first-page":"00794","volume":"23","author":"Raghavendra","year":"2024"},{"key":"10.1016\/j.ejca.2025.116161_bib5","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/cancers13051078","article-title":"Breast cancer brain metastasis\u2014overview of disease state, treatment options and future perspectives","volume":"13","author":"Watase","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116161_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101213","article-title":"Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry","volume":"8","author":"Riecke","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116161_bib7","first-page":"i1","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023: featured updates to the NCCN Guidelines","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2025.116161_bib10","first-page":"2305","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116161_bib12","first-page":"157","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100596","article-title":"Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116161_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116161_bib15","first-page":"157","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib16","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116161_bib17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib18","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 4.2023). NCCN. 2023. NCCN.org (accessed July 28, 2023)."},{"key":"10.1016\/j.ejca.2025.116161_bib19","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib20","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology\u2013friends of cancer research brain metastases working group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/EDBK_175338","article-title":"Breast cancer in the central nervous system: multidisciplinary considerations and management","volume":"37","author":"Lin","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejca.2025.116161_bib22","article-title":"Exclusion of patients with brain metastases from cancer clinical trials","volume":"22","author":"Patel","year":"2020","journal-title":"NeuroOncol"},{"key":"10.1016\/j.ejca.2025.116161_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2025.116161_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116161_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101474","volume":"14","author":"Dotan","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2025.116161_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","article-title":"Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2025.116161_bib28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A Review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejca.2025.116161_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41467-024-55090-4","article-title":"Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265 2 prior lines of chemotherapy: a phase Ib study","volume":"16","author":"Fan","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.116161_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-020-05995-7","article-title":"Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase","volume":"185","author":"Sachdev","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2025.116161_bib31","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220166","article-title":"RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment","volume":"5","author":"Gong","year":"2023","journal-title":"Radio Imaging Cancer"},{"key":"10.1016\/j.ejca.2025.116161_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-017-4304-7","article-title":"Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial","volume":"165","author":"Cort\u00e9s","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2025.116161_bib33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib34","unstructured":"Helwick C. TUXEDO-1 Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases - The ASCO Post. 2022; published online Sept 5. \u3008https:\/\/ascopost.com\/news\/may-2022\/tuxedo-1-efficacy-of-t-dxd-for-patients-with-her2-positive-breast-cancer-and-active-brain-metastases\/\u3009 (accessed Jan 26, 2023)."},{"key":"10.1016\/j.ejca.2025.116161_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz Batista","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116161_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.08.001","article-title":"The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ejca.2025.116161_bib37","first-page":"1","article-title":"TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases","author":"Marhold","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103209","article-title":"187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)","volume":"9","author":"Bartsch","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116161_bib39","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.116161_bib40","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116161_bib41","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD13-07","article-title":"Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer","volume":"81","author":"Di\u00e9ras","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116161_bib42","first-page":"1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116161_bib43","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1016\/j.annonc.2024.08.380","volume":"35","author":"Tolaney","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.116161_bib46","unstructured":"FDA. Cancer Clinical Trial Eligibility Criteria: Brain Metastases. Guidance for Industry. 2020 \u3008https:\/\/www.fda.gov\/media\/121317\/download\u3009."},{"key":"10.1016\/j.ejca.2025.116161_bib47","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116161_bib48","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:38:28Z","timestamp":1773895108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"alternative-id":["S0959804925010470"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116161","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116161"}}